Fifth Third Bancorp increased its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 7.7% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 445,222 shares of the company’s stock after buying an additional 31,654 shares during the quarter. Eli Lilly and Company comprises approximately 1.5% of Fifth Third Bancorp’s portfolio, making the stock its 10th largest holding. Fifth Third Bancorp’s holdings in Eli Lilly and Company were worth $403,095,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in LLY. Tidemark LLC acquired a new stake in shares of Eli Lilly and Company during the 4th quarter worth about $29,000. Core Wealth Advisors Inc. grew its holdings in shares of Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock worth $29,000 after purchasing an additional 32 shares during the last quarter. Lynx Investment Advisory bought a new position in shares of Eli Lilly and Company in the second quarter valued at about $32,000. Frank Rimerman Advisors LLC acquired a new position in Eli Lilly and Company during the 4th quarter worth about $37,000. Finally, St. Johns Investment Management Company LLC grew its holdings in Eli Lilly and Company by 123.3% during the 4th quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock worth $39,000 after acquiring an additional 37 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.
Eli Lilly and Company Trading Up 0.2 %
Shares of LLY traded up $2.00 during trading hours on Wednesday, reaching $951.97. The stock had a trading volume of 2,497,504 shares, compared to its average volume of 3,101,510. The firm has a 50-day moving average of $881.72 and a 200 day moving average of $810.11. The company has a quick ratio of 1.03, a current ratio of 1.35 and a debt-to-equity ratio of 1.90. The company has a market cap of $904.76 billion, a P/E ratio of 139.10, a P/E/G ratio of 1.81 and a beta of 0.41. Eli Lilly and Company has a 52 week low of $516.57 and a 52 week high of $967.00.
Eli Lilly and Company Announces Dividend
Insider Activity
In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total value of $1,660,068.00. Following the completion of the transaction, the insider now owns 98,554,195 shares in the company, valued at $79,730,343,755. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of the business’s stock in a transaction dated Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total value of $1,660,068.00. Following the sale, the insider now directly owns 98,554,195 shares in the company, valued at $79,730,343,755. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the transaction, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at $5,842,821.10. The disclosure for this sale can be found here. Insiders have sold 1,214,704 shares of company stock worth $1,066,841,316 in the last 90 days. Corporate insiders own 0.13% of the company’s stock.
Analyst Ratings Changes
A number of equities analysts have recently issued reports on the stock. Truist Financial reiterated a “buy” rating and set a $1,000.00 target price (up from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Argus lifted their target price on Eli Lilly and Company from $770.00 to $840.00 and gave the company a “buy” rating in a research note on Tuesday, May 14th. Bank of America boosted their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a research report on Friday, August 9th. Morgan Stanley reiterated an “overweight” rating and issued a $1,023.00 price target on shares of Eli Lilly and Company in a report on Friday, July 5th. Finally, JPMorgan Chase & Co. boosted their price objective on Eli Lilly and Company from $900.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. Two analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $956.88.
Read Our Latest Analysis on LLY
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
See Also
- Five stocks we like better than Eli Lilly and Company
- What is Short Interest? How to Use It
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- The Significance of Brokerage Rankings in Stock Selection
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- What Does a Stock Split Mean?
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.